This drug may result in weight loss for 3 years in adults without diabetes

Taking tirzepatide drug once a week may produce clinically meaningful and sustained weight loss for at least three years in adults with overweight or obesity who do not have diabetes according to new researchThe findings also indicate that females and those without obesityrelated complications may be more responsive to tirzepatide treatment said researchers at the European Congress on Obesity ECO in Malaga SpainThe study led by Dr Luca Busetto from the University of Padova in Italy and colleagues from Eli Lilly and Company that manufacture tirzepatide is a continuation of the SURMOUNT1 phase 3 trial of tirzepatide a medication approved in the EU and USA for obesity and type 2 diabetes treatmentThe trial uncovered no new safety issues the most common side effects were nausea diarrhoea and constipationldquoOur longterm analysis of tirzepatide establishes that clinically relevant weight loss can be sustained for up to 3 years in a diverse population of adults with overweight or obesity but not diabetes regardless of age BMI and duration of obesity at the outset of the studyrdquo said BusettoBut not everyone responds to medication to the same degree and we identified a greater chance of successful weight loss in a group with a higher proportion of females and those with no medical conditions linked to obesity Busetto addedTirzepatide works by mimicking the glucagonlike peptide1 GLP1 and glucosedependent insulinotropic polypeptide GIP hormones that are naturally secreted by the gut after a meal which stimulates insulin secretionIt also reduces appetite by slowing down the time it takes the stomach to empty and interacting with areas in the brain harbouring GLP1 receptors to signal fullness or satietyTirzepatide was approved in November 2023 by the US Food and Drug Administration FDA Zepbound and in the EU in June 2024 Mounjaro for weight management in adults with obesity or overweight with at least one weightrelated condition such as high blood pressure type 2 diabetes or high cholesterolThe findings could provide deeper insights into the efficacy of tirzepatide across different demographics and medical histories potentially allowing for more individualised treatment plans and goals said the teamThis story has been sourced from a third party syndicated feed agencies Midday accepts no responsibility or liability for its dependability trustworthiness reliability and data of the text Midday managementmiddaycom reserves the sole right to alter delete or remove without notice the content in its absolute discretion for any reason whatsoeveratOptionskeyd0ddb8ef8f1a62a8cdd22fac27fc5ea7formatiframeheight90width728params